



WHAT IS CLAIMED IS:

1. A compound of formula (I)



wherein A represents A1 or A2



R is unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, heteroaryl, heteroaryl-(C₁-C₁₀-alkyl)-, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)-, C₃-C₁₀-cycloalkyl, polycycloalkyl, C₂-C₁₀-alkenyl or C₂-C₁₀-alkynyl,

where the substituents are chosen from halogen, -CN, C₁-C₁₀-alkyl, -NO₂, -OR₁, -C(O)OR₁, -O-C(O)R₁, -NR₁R₂, -NHC(O)R₁, -C(O)NR₁R₂, -SR₁, -S(O)R₁, -SO₂R₁, -NH-SO₂R₁, -SO₂NR₁R₂, -C(S)NR₁R₂, -NHC(S)R₁, -O-SO₂R₁, -SO₂-O-R₁, oxo, -C(O)R₁, -C(NH)NH₂, heterocyclyl, C₃-C₁₀-cycloalkyl, aryl-(C₁-C₆-alkyl)-, aryl, heteroaryl, trifluoromethyl, trifluoromethylsulfanyl and trifluoromethoxy,

and aryl, heterocyclyl and heteroaryl may in turn be at least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen, trifluoromethyl, trifluoromethoxy or OH;

Ar is unsubstituted or at least monosubstituted aryl or heteroaryl;

where the substituents are chosen from halogen, -CN, NO₂, C₁-C₁₀-alkyl, -OR₁, -C(O)OR₁, -O-C(O)R₁, -NR₁R₂, -NHC(O)R₁, -C(O)NR₁R₂, -NHC(S)R₁, -C(S)NR₁R₂, -SR₁, -S(O)R₁, -SO₂R₁, -NHSO₂R₁, -SO₂NR₁R₂, -O-SO₂R₁, -SO₂-O-R₁, aryl, heteroaryl, aryl-(C₁-C₆-alkyl)-, formyl, trifluoromethyl and trifluoromethoxy,

and aryl and heteroaryl may in turn be at least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen, trifluoromethyl, trifluoromethoxy or OH;

R₁ and R₂, independently from each other, are hydrogen;

unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, C₃-C₁₀-cycloalkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)- or heteroaryl, where the substituents are chosen from halogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, CN, NO₂, NH₂, (C₁-C₆-alkyl) amino-, di(C₁-C₆-alkyl)amino-, OH, COOH, -COO-(C₁-C₆-alkyl), -CONH₂, formyl, trifluoromethyl and trifluoromethoxy;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O and S;

aryl is phenyl, indanyl, indenyl or naphthyl;

heterocyclyl is a 5 to 10-membered, aliphatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O and S;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof;

with the proviso that A is not -C(O)NH(C₁-C₆-alkyl), when Ar is phenyl which is at least monosubstituted with heterocyclyl or heteroaryl containing nitrogen.

2. The compound according to claim 1, wherein in the formula (I)

A is A1;

R is unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, heteroaryl, heteroaryl-(C₁-C₁₀-alkyl)-, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)-, C₃-C₁₀-cycloalkyl, polycycloalkyl, C₂-C₁₀-alkenyl or C₂-C₁₀-alkinyl,

where the substituents are chosen from halogen, -CN, C₁-C₁₀-alkyl, -NO₂, -OR₁, -C(O)OR₁, -O-C(O)R₁, -NR₁R₂, -NHC(O)R₁, -C(O)NR₁R₂, -SR₁, -S(O)R₁, -SO₂R₁, -NHSO₂R₁, -SO₂NR₁R₂, -C(S)NR₁R₂, -NHC(S)R₁, -O-SO₂R₁, -SO₂-O-R₁, oxo, -C(O)R₁, -C(NH)NH₂, heterocyclyl, C₃-C₁₀-cycloalkyl, aryl-(C₁-C₆-alkyl)-, aryl, heteroaryl, trifluoromethyl, trifluoromethylsulfanyl and trifluoromethoxy,

and aryl, heterocyclyl and heteroaryl may in turn be at least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen, trifluoromethyl, trifluoromethoxy or OH;

R₁ and R₂, independently from each other, are hydrogen;

unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, C₃-C₁₀-cycloalkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)- or heteroaryl, where the substituents are chosen from halogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, CN, NO₂, NH₂, (C₁-C₆-alkyl)amino-, di(C₁-C₆-alkyl)amino-, OH, COOH, -COO-(C₁-C₆-alkyl), -CONH₂, formyl, trifluoromethyl and trifluoromethoxy;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O and S;

aryl is phenyl, indanyl, indenyl or naphthyl;

heterocyclyl is a 5 to 10-membered, aliphatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O and S;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

3. The compound according to claim 1, wherein in the formula (I)

R is unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)-, C₃-C₁₀-cycloalkyl, heteroaryl or heteroaryl-(C₁-C₁₀-alkyl)-,

where the substituents are chosen from halogen, -CN, C₁-C₁₀-alkyl, -NO₂, -OR₁, -C(O)OR₁, -O-C(O)R₁, -NR₁R₂, -NHC(O)R₁, -C(O)NR₁R₂, -SR₁, -S(O)R₁, -SO₂R₁, -NH-SO₂R₁, -SO₂NR₁R₂, -C(S)NR₁R₂, -NHC(S)R₁, -O-SO₂R₁, -SO₂-O-R₁, oxo, -C(O)R₁, -C(NH)NH₂, heterocyclyl, C₃-C₁₀-cycloalkyl, aryl-(C₁-C₆-alkyl)-, aryl, heteroaryl, trifluoromethyl, trifluoromethylsulfanyl and trifluoromethoxy,

and aryl, heterocyclyl and heteroaryl may in turn be at least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen, trifluoromethyl, trifluoroethoxy or OH;

R₁ and R₂, independently from each other, are

hydrogen;

unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, C₃-C₁₀-cycloalkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, heterocyclyl,

heterocyclyl-(C₁-C₁₀-alkyl)- or heteroaryl, where the substituents are chosen from halogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, CN, NO₂, NH₂, (C₁-C₆-alkyl)amino-, di(C₁-C₆-alkyl)amino-, OH, COOH, -COO-(C₁-C₆-alkyl), -CONH₂, formyl, trifluoromethyl and trifluoromethoxy;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O and S;

aryl is phenyl, indanyl, indenyl or naphthyl;

heterocyclyl is a 5 to 10-membered, aliphatic, mono- or bicyclic heterocycle, containing one or more heteroatoms chosen from N, O and S;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

4. The compound according to claim 1, wherein in the formula (I)

Ar is unsubstituted or at least monosubstituted phenyl, pyridinyl, pyrimidinyl, pyrazolyl, thiophenyl, isoxazolyl, benzo[b]thiophenyl, benzodioxolyl or thiazolo[3,2-b][1,2,4]-thiazolyl,

where the substituents are chosen from halogen, -CN, NO₂, C₁-C₁₀-alkyl, -OR₁, -C(O)OR₁, -O-C(O)R₁, -NR₁R₂, -NHC(O)R₁, -C(O)NR₁R₂, -NHC(S)R₁, -C(S)NR₁R₂, -SR₁, -S(O)R₁, -SO₂R₁, -NH-SO₂R₁, -SO₂NR₁R₂, -O-SO₂R₁, -SO₂-O-R₁, aryl, heteroaryl, aryl-(C₁-C₆-alkyl)-, formyl, trifluoromethyl and trifluoromethoxy,

and aryl and heteroaryl may in turn be at least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen, trifluoromethyl, trifluoromethoxy or OH;

R₁ and R₂, independently from each other, are

hydrogen;

unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, C₃-C₁₀-cycloalkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)- or heteroaryl, where the substituents are chosen from halogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, CN, NO₂, NH₂, (C₁-C₆-alkyl) amino-, di(C₁-C₆-alkyl)amino-, OH, COOH, -COO-(C₁-C₆-alkyl), -CONH₂, formyl, trifluoromethyl and trifluoromethoxy;

heteroaryl is a 5 to 10-membered aromatic, mono- or bicyclic heterocycle, containing one or more heteroatoms chosen from N, O and S;

aryl is phenyl, indanyl, indenyl or naphthyl;

heterocyclyl is a 5 to 10-membered aliphatic, mono- or bicyclic heterocycle, containing one or more heteroatoms chosen from N, O and S;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

5. The compound according to claim 1, wherein in the formula (I)

A is A1;

R is unsubstituted or at least monosubstituted aryl-(C₁-C₆-alkyl)- or heteroaryl-(C₁-C₆-alkyl)-,

where the substituents are chosen from halogen, C₁-C₆-alkyl, -OH, -O-aryl, C₁-C₆-alkoxy, -O-(C₁-C₆-alkyl)-N(C₁-C₆-alkyl)₂, -C(O)OH, -C(O)O-(C₁-C₆-alkyl), -NH₂, -N(C₁-C₆-alkyl)₂, -NH(C₁-C₆-alkyl), -NH(C₁-C₁₀-cycloalkyl), -C(O)NH₂, -C(O)NH-heteroaryl, -C(O)NH-(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl), -SO₂NH₂, -C(O)-heterocyclyl, -C(NH)NH₂, heterocyclyl, aryl-(C₁-C₆-alkyl)-, aryl, trifluoromethyl, and trifluoromethoxy,

and aryl, heterocyclyl and heteroaryl may in turn be at least monosubstituted with C₁-C₃-alkyl, C₁-C₃-alkoxy, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy or OH;

heteroaryl is imidazolyl, thiophenyl, furanyl, isoxazolyl, pyridinyl, pyrimidinyl, benzoimidazolyl, indolyl or benzodioxolyl;

aryl is phenyl or naphthyl;

heterocyclyl is morpholinyl, piperazinyl or piperidinyl;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

6. The compound according to claim 1, wherein in the formula (I)

A is A1;

Ar is unsubstituted or at least monosubstituted phenyl, pyridin-4-yl or pyrimidin-4-yl,

where the substituents are chosen from halogen, C₁-C₆-alkyl, -OH, C₁-C₆-alkoxy, -C(O)OH, -C(O)O-(C₁-C₆-alkyl), -NH₂, -N(C₁-C₆-alkyl)₂, -NH(C₁-C₆-alkyl), -NH(C₁-C₁₀-cycloalkyl), -NH(heterocyclyl-(C₁-C₆-alkyl-)), -NH(aryl-(C₁-C₆-alkyl-)), -C(O)NH₂, -C(O)NH-(C₁-C₆-alkyl), aryl, and heteroaryl,

and aryl, heterocyclyl and heteroaryl may in turn be at least monosubstituted with C₁-C₃-Alkyl, C₁-C₃-alkoxy, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy or OH;

heteroaryl is pyridinyl or pyrimidinyl;

aryl is phenyl or naphthyl;

heterocyclyl is morpholinyl, piperazinyl or piperidinyl;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

7. The compound according to claim 1, wherein in the formula (I)

A is A1;

R is unsubstituted or at least monosubstituted benzyl, phenylethyl-, phenylpropyl-, pyridinylmethyl-, pyridinylethyl- or pyridinylpropyl-,

where the substituents are chosen from chlorine, bromine, fluorine, trifluoromethyl and carboxy;

Ar is unsubstituted or at least monosubstituted pyridin-4-yl, pyrimidin-4-yl or phenyl,

where the substituents are chosen from methylamino-, ethylamino-, propylamino-, butylamino-, hydroxy, methoxy, ethoxy, methyl, ethyl, propyl, (phenylethyl)amino-, benzylamino- and (morpholinylethyl)amino-;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

8. The compound according to claim 1 chosen from

6-(2-butylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide,

6-(4-hydroxy-3-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide,

6-(4-hydroxy-3,5-dimethyl-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide,

6-(4-hydroxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide,

6-(2-ethylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-(3-chloro-4-hydroxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-(4-hydroxy-3,5-dimethyl-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

4-([6-(4-hydroxy-3,5-dimethyl-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carbonyl]-amino)-methyl)-benzoic acid,

4-([6-(4-hydroxy-3-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carbonyl]-amino)-methyl)-benzoic acid,

6-(2-butylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (pyridin-3-yl-methyl)-amide,

6-(3-fluoro-4-hydroxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-(4-hydroxy-3-methyl-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-[2-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-(4-hydroxy-3-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-(2-methylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

R-3-oxo-6-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-2,3-dihydro-pyridazine-4-carboxylic acid (3-phenyl-propyl)-amide,

6-(4-hydroxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

3-oxo-6-pyridin-4-yl-N-[4-(trifluoromethyl)benzyl]-2,3-dihydropyridazine-4-carboxamide,

3-oxo-6-pyridin-4-yl-2,3-dihydro-pyridazine-4-carboxylic acid 4-bromo-benzylamide,

3-oxo-6-pyridin-4-yl-N-(pyridin-3-ylmethyl)-2,3-dihydropyridazine-4-carboxamide,

N-(2,4-dichlorobenzyl)-3-oxo-6-pyridin-4-yl-2,3-dihydropyridazine-4-carboxamide,

3-oxo-6-pyridin-4-yl-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-2-fluoro-benzylamide, and

N-(4-chlorobenzyl)-3-oxo-6-pyridin-4-yl-2,3-dihydropyridazine-4-carboxamide;

the racemates, enantiomers, diastereoisomers and mixtures thereof, and the tautomers or the physiologically acceptable salts thereof.

9. A method for inhibiting GSK-3 β or the phosphorylation of the Tau protein in a patient requiring such treatment comprising administering a physiologically active amount of a compound according to claim 1.

10. A method for inhibiting GSK-3 β or the phosphorylation of the Tau protein in a patient requiring such treatment comprising administering a physiologically active amount of a compound according to claim 2.

11. A method for inhibiting GSK-3 β or the phosphorylation of the Tau protein in a patient requiring such treatment comprising administering a physiologically active amount of a compound according to claim 3.

12. A method for inhibiting GSK-3 β or the phosphorylation of the Tau protein in a patient requiring such treatment comprising administering a physiologically active amount of a compound according to claim 4.

13. A method for inhibiting GSK-3 β or the phosphorylation of the Tau protein in a patient requiring such treatment comprising administering a physiologically active amount of a compound according to claim 5.

14. A method for inhibiting GSK-3 β or the phosphorylation of the Tau protein in a patient requiring such treatment comprising administering a physiologically active amount of a compound according to claim 6.

15. A method for inhibiting GSK-3 β or the phosphorylation of the Tau protein in a patient requiring such treatment comprising administering a physiologically active amount of a compound according to claim 7.

16. A method for inhibiting GSK-3 β or the phosphorylation of the Tau protein in a patient requiring such treatment comprising administering a physiologically active amount of a compound according to claim 8.

17. A method for treating a patient suffering from a disease chosen from neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral

neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome, syndrome X, immunodeficiency and cancer, which method comprises administering a physiologically active amount of a compound according to claim 1.

18. A method for treating a patient suffering from a disease chosen from neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome, syndrome X, immunodeficiency and cancer, which method comprises administering a physiologically active amount of a compound according to claim 2.

19. A method for treating a patient suffering from a disease chosen from neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome, syndrome X, immunodeficiency and cancer, which method comprises administering a physiologically active amount of a compound according to claim 3.

20. A method for treating a patient suffering from a disease chosen from neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome, syndrome X, immunodeficiency and cancer, which method comprises administering a physiologically active amount of a compound according to claim 4.

21. A method for treating a patient suffering from a disease chosen from neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome, syndrome X, immunodeficiency and cancer, which method comprises administering a physiologically active amount of a compound according to claim 5.

22. A method for treating a patient suffering from a disease chosen from neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome, syndrome X, immunodeficiency and cancer, which method comprises administering a physiologically active amount of a compound according to claim 6.

23. A method for treating a patient suffering from a disease chosen from neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome, syndrome X, immunodeficiency and cancer, which method comprises administering a physiologically active amount of a compound according to claim 7.

24. A method for treating a patient suffering from a disease chosen from neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome, syndrome X,

immunodeficiency and cancer, which method comprises administering a physiologically active amount of a compound according to claim 8.

25. The method according to claim 17, wherein the neurodegenerative disease is chosen from Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration and Pick's disease.


26. The method according to claim 17, wherein the disease is chosen from type-II-diabetes and Alzheimer's disease.

27. A pharmaceutical preparation comprising an effective dose of at least one compound or a physiologically acceptable salt thereof as defined in claim 1 and a physiologically acceptable carrier.

28. The pharmaceutical preparation according to claim 27, which pharmaceutical preparation is in the form of a pill, tablet, lozenge, coated tablet, granule, capsule, hard or soft gelatin capsule, aqueous solution, alcoholic solution, oily solution, syrup, emulsion suspension, pastille, suppository, solution for injection or infusion, ointment, tincture, cream, lotion, powder, spray, transdermal therapeutic systems, nasal spray, aerosol mixture, microcapsule, implant, rod or plaster.

29. A method for the synthesis of a compound of formula (I) according to claim 1, wherein

a) a compound of formula (IV)



wherein Y1 is halogen, $B(OH)_2$ or $Sn(C_1-C_{10}\text{-alkyl})$ and


Y2 is H or a protecting group,

is converted with Ar-Z in presence of a palladium complex, wherein Z is

$B(OH)_2$, $B(C_1-C_{10}\text{-alkoxy})_2$, $Sn(C_1-C_{10}\text{-alkyl})_3$, $Zn-(C_1-C_{10}\text{-alkyl})$ or halogen,

or

b) with the proviso that in formula (I) A is A1, a compound of formula (II)



wherein X is -OH, $C_1-C_{10}\text{-alkoxy}$, chlorine or $-O-C(O)O-(C_1-C_{10}\text{-alkyl})$, is

converted with RNH_2 .